SoftOx Solutions AS — Regulatory Filings 2021

Jun 7, 2021

SoftOx Solutions AS: The Danish Medicines Agency has given a conditional approval for the first study in humans for SoftOx Inhalation Solution (SIS) for the treatment of respiratory infections.

SoftOx Solutions AS: The Danish Medicines Agency has given a conditional approval for the first study in humans for SoftOx Inhalation Solution (SIS) for the treatment of respiratory infections.

SoftOx Solutions AS (SoftOx) aims to develop an inhalation solution (SIS) for the treatment of respiratory tract infections. This has the potential to be a breakthrough in the future treatment of respiratory infections, including viruses, bacteria and fungal infections.

“After an intensive research phase, we are very satisfied that the Danish Medicines Agency (DKMA) considers our documentation positively and has given a conditional approval to be able to start the study”, says Medical Director Glenn Gundersen. “The conditions that have been communicated are related to additional safety data and the company is already working on completing the data as requested. The data will be provided in due time and we believe that the study can be initiated during the autumn.”

For further information, please contact:

Geir Almås, CEO of SoftOx Solutions AS, or

Glenn Gundersen, Medical Director in SoftOx Solutions AS

Mail: ir@soft-ox.com

Phone: Front Desk: (+47) 948-59-599

About SoftOx Solutions AS

SoftOx Solutions AS is a Norwegian BioTech company listed on Euronext Growth

Oslo. Our Vison is “Helping the world fighting infections - developing new ways

of eradicating infections and fighting antimicrobial resistance”. We are working

to combat major threats to human health, namely the emergence of antimicrobial

resistance (AMR), biofilm infections in chronic wounds and the spread of

viruses. For more information on SoftOx, visit www.soft-ox.com.